Serum 1,5-Anhydroglucitol (GlycoMark™): A Short-Term Glycemic Marker
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
1,5-Anhydroglucitol (1,5-AG), the 1-deoxy form of glucose, has been measured and used clinically in Japan for over a decade to monitor short-term glycemic control. Evaluation of glucose control otherwise requires measuring plasma glucose or glycated proteins whose levels reflect average glucose concentration over the half-life of the protein analyzed. Hemoglobin A1c measurements reflect blood glucose levels over that past 2-3 months, while fructosamine can be used to evaluate glycemic control over 10-14 days. In contrast, 1,5-AG levels in blood respond within 24 h as a result of glucose's competitive inhibition of 1,5-AG reabsorption in the kidney tubule. When glucose levels rise, even transiently, urinary loss of 1,5-AG occurs, and circulating levels fall. Because of changes in renal hemodynamics in normal pregnancies, 1,5-AG appears of limited usefulness in evaluation of gestational diabetes. However, the characteristics of 1,5-AG levels in patients with moderate to near-normal glycemic control suggest that it may be a valuable complement to frequent self-monitoring or continuous monitoring of plasma glucose to confirm stable glycemic control. Measurements performed daily or weekly in a given patient would suggest that overall glycemic control has been stable or improved if 1,5-AG levels are stable or increasing. If 1,5-AG levels fall, greater attention to glucose monitoring and both lifestyle and medical management could be prescribed to correct the glycemic excursions that would underlie such changes. The behavior of this analyte is different from all others used in the management of diabetes, creating potential opportunities for its use in clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, GLP-1RAs exhibit pronounced efficacy in optimizing blood lipid profiles by effectively suppressing chylomicron secretion in the intestine, thereby mitigating the occurrence of postprandial hyperlipidemia.447”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [447]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 39 · Cited by 187
Research works printed but not linked: 2
- Stickle D, 1997, Am J Physiol, 273, E821
- Yamanouchi T, 1990, Am J Physiol, 258, E423
Metadata
- Authors
- Buse, J. B., Freeman, J. L. R., Edelman, S. V., Jovanovic, L., & McGill, J. B.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- BioEmerge Partners, Inc., Winston-Salem, North Carolina
- University of California San Diego (US)
- Sansum Medical Research Institute, Santa Barbara, California
- Washington University in St. Louis (US)
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2003-06
- Volume
- 5
- Issue
- 3
- Pages
- 355-363
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W1965776430
- Cited by
- 187
- References
- 39
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 16 · 2023: 7 · 2022: 14 · 2021: 8 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 10 · 2016: 9 · 2015: 15 · 2014: 12 · 2013: 10 · 2012: 8
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
- Locations
- Diabetes Technology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- McGill University
- U.S. Food and Drug Administration
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- 1,5-anhydroglucitol, glycemic control monitoring, diabetes management, tubular reabsorption, urinary excretion, gestational diabetes mellitus, self-monitoring of blood glucose, glycated proteins
- MeSH terms
- Blood Glucose, Deoxyglucose, Environmental Monitoring, Humans, Hyperglycemia, Isomerism, Japan, Gas Chromatography-Mass Spectrometry, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum 1,5-Anhydroglucitol (GlycoMark™): A Short-Term Glycemic Marker. https://app.cochat.ai/papers/10.1089/152091503765691839
- The paper
- Buse, J. B., Freeman, J. L. R., Edelman, S. V., Jovanovic, L., & McGill, J. B. (2003). Serum 1,5-Anhydroglucitol (GlycoMark™): A Short-Term Glycemic Marker. Diabetes Technology & Therapeutics. https://doi.org/10.1089/152091503765691839
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.